<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Insulin NPH: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Insulin NPH: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Insulin NPH: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11550" href="/d/html/11550.html" rel="external">see "Insulin NPH: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12804" href="/d/html/12804.html" rel="external">see "Insulin NPH: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F2135494"><span class="drugH1">Brand Names: US</span>
<ul>
<li>HumuLIN N KwikPen [OTC];</li>
<li>HumuLIN N [OTC];</li>
<li>NovoLIN N FlexPen ReliOn [OTC];</li>
<li>NovoLIN N FlexPen [OTC];</li>
<li>NovoLIN N ReliOn [OTC];</li>
<li>NovoLIN N [OTC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F2135498"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Insulin, Intermediate-Acting</li></ul></div>
<div class="block doa drugH1Div" id="F2135530"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Insulin NPH is an intermediate-acting basal insulin formulation. Insulin requirements vary between patients; monitor glucose levels frequently and individualize dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc2823b3-202c-4a44-a2d1-58b5084839e6">Diabetes mellitus, type 1, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 1, treatment:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Insulin NPH must be used concomitantly with rapid- or short-acting insulins (ie, multiple daily injection regimen). <b>The total daily doses (TDD) presented below are expressed as the</b>
<b>total units/kg/day of all insulin formulations combined.</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General insulin dosing:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Initial TDD:</b></i>
<b>SUBQ: </b>~0.4 to 0.5 units/kg/day; conservative initial doses of 0.2 to 0.4 units/kg/day may be considered to avoid the potential for hypoglycemia; higher initial doses may be required in patients with obesity, or who are sedentary or presenting with ketoacidosis (AACE [Handelsman 2015]; ADA 2022).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Usual TDD maintenance range:</i></b>
<b>SUBQ: </b>0.4 to 1 units/kg/day in divided doses (ADA 2022).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Division of TDD (multiple daily injections):</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">Basal insulin: <b>SUBQ: </b>Generally, 40% to 50% of the TDD is given as basal insulin (intermediate- or long-acting) (AACE [Handelsman 2015]; ADA 2022). Insulin NPH may be administered in 2 divided doses daily (either as equally divided doses, or as ~<sup>2</sup>/<sub>3</sub> of the dose before the morning meal and ~<sup>1</sup>/<sub>3</sub> of the dose before the evening meal or at bedtime). Alternatively, dividing insulin NPH into 3 or 4 doses per day may reduce hypoglycemic risk and establish more consistent basal insulin profile (Peters 2013).</p>
<p style="text-indent:-2em;margin-left:8em;">Prandial insulin: <b>SUBQ: </b>The remaining portion (ie, 50% to 60%) of the TDD is then divided and administered before, at, or just after mealtimes depending on the formulation (eg, short-, rapid-, or ultra-rapid acting) (AACE [Handelsman 2015]; ADA 2022).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Dosage adjustment:</b> Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. Treatment and monitoring regimens must be individualized. To minimize hypoglycemia risk, basal insulins are generally titrated once or twice weekly (eg, every 3 or 7 days) (ADA 2022; McCall 2012).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>
<b>: </b>Preferred in patients with symptomatic hyperglycemia (eg, weight loss, polydipsia, polyuria) or with ketonuria; may also be used in patients with severe hyperglycemia (eg, fasting glucose &gt;250 mg/dL, random glucose consistently &gt;300 mg/dL, HbA<sub>1c</sub> &gt;9%), or if glycemic goals are not met despite adequately titrated metformin with or without other noninsulin agents (ADA 2022; Wexler 2022). Consider discontinuation or a dose reduction of sulfonylureas and thiazolidinediones when initiating basal insulin therapy (ADA/EASD [Davies 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Initial:</i></b>
<b>SUBQ: </b>10 units/day <b>or</b> 0.1 to 0.2 units/kg/day administered as a single dose (usually at bedtime) (ADA 2022; Lipska 2017). In patients with HbA<sub>1c</sub> &gt;8%, fasting glucose &gt;250 mg/dL, or insulin resistance, 0.2 to 0.3 units/kg/day is recommended (AACE/ACE [Garber 2020]; Wexler 2022). Some experts use a minimum of 10 units/day and do not exceed 20 units/day for the initial dose (Wexler 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Dosage adjustment</i></b>
<b>
<i>:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>For persistently elevated fasting plasma glucose: SUBQ: </b>Increase daily dose by 2 to 4 units <b>or</b> by 10% to 20% every 2 to 3 days to achieve fasting plasma glucose target while avoiding hypoglycemia (AACE/ACE [Garber 2020]; ADA 2022; Wexler 2022).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>For elevated HbA<sub>1c </sub>despite achieving fasting plasma glucose target: SUBQ: </b>Encourage lifestyle modifications. Consider adding other medications (eg, a glucagon-like peptide-1 receptor agonist, prandial insulin before the largest meal); in patients using NPH insulin once daily, an alternative is to switch to a twice-daily regimen by administering ~80% of the current daily dose in 2 divided doses (eg, two-thirds of the daily dose in the morning and one-third of the daily dose at bedtime). In some patients, higher insulin NPH doses (eg, &gt;0.5 units/kg/day) may provide diminishing additional improvements in HbA<sub>1c</sub> (AACE/ACE [Garber 2020]; ADA 2022).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>For hypoglycemia: SUBQ: </b>For unexplained mild to moderate hypoglycemia, consider decreasing daily dose by 10% to 20% (ADA 2022); for severe hypoglycemia requiring assistance from another person, or if blood glucose &lt;40 mg/dL, consider decreasing daily dose by 20% to 50% (AACE/ACE [Garber 2020]; Wexler 2022). <b>Note:</b> Use of long-acting basal analogs may be preferred over insulin NPH if hypoglycemia is a primary concern (AACE/ACE [Garber 2020]; ADA 2022).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Dosage adjustment when adding prandial insulin: SUBQ: </b>In patients whose glucose levels are close to target (eg, HbA<sub>1c</sub> &lt;8%), consider decreasing the basal insulin daily dose by 4 units <b>or</b> by 10% (ADA 2022).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Preoperative dosage adjustment: </b>Dose reductions are applied to the morning and/or evening insulin NPH doses as follows:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Evening scheduled dosage adjustment:</i>
<b> SUBQ: </b>Reduce insulin NPH dose by 10% to 25% the evening before the procedure; may administer the full dose if preoperative hypoglycemia risk is low (eg, glucose levels generally &gt;200 mg/dL) (ES [Umpierrez 2012]; Khan 2022).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Morning scheduled dosage adjustment:</i>
<b>SUBQ: </b>For patients not using prandial insulin, reduce insulin NPH dose by 10% to 25% the morning of the procedure; may administer the full dose if preoperative hypoglycemia risk is low (eg, glucose levels generally &gt;200 mg/dL). For patients using prandial insulin, omit prandial insulin after fasting begins and administer one-half to two-thirds of the total morning insulin dose (basal + prandial) as insulin NPH the morning of the procedure (ES [Umpierrez 2012]; Khan 2022).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="87b665ef-68eb-453a-80ad-91aa786100ef">Patients with diabetes receiving enteral feedings</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Patients with diabetes receiving enteral feedings (ADA 2022): Note:</b> TDD of insulin is divided into a basal component (intermediate- or long-acting insulin) and nutritional and correctional components (regular insulin or rapid-acting insulins).</p>
<p style="text-indent:-2em;margin-left:4em;">Basal component: <b>SUBQ:</b> Continue previous basal insulin dose <b>or</b> administer 30% to 50% of TDD as insulin NPH; if basal insulin naive, administer insulin NPH 5 units every 12 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="34bfe506-818e-4fc3-8d8a-c903d351487b">Patients with diabetes undergoing surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Patients with diabetes undergoing surgery: SUBQ: </b>On the evening before surgery or procedure, reduce the usual dose by 25%; on the morning of surgery or procedure, reduce the usual dose by 25% to 50% (ADA 2022; Pichardo-Lowden 2012).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Conversion from long-acting insulin analogs to insulin NPH: </b>Consider initiating insulin NPH at 80% (eg, 20% reduction) of previous basal insulin total daily dose; administer as a single dose (usually at bedtime) or in 2 divided doses (ADA 2022; Lipska 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991326"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>
<div class="block doha drugH1Div" id="F50988673"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>
<div class="block doe drugH1Div" id="F2328823"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F2135529"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12804" href="/d/html/12804.html" rel="external">see "Insulin NPH: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Insulin NPH is an intermediate-acting insulin formulation. Insulin doses should be individualized based on patient needs; adjustments may be necessary with changes in physical activity, meal patterns, acute illness, or with changes in renal or hepatic function. Insulin requirements vary dramatically between patients and dictate frequent monitoring and close medical supervision. Insulin regimens vary widely by region, practice, and institution; consult institution-specific guidelines.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5956846-9e6c-4def-954b-a126316b2bbe">Diabetes mellitus, type 1</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 1: </b>
<b>Note:</b> For basal insulin coverage, long-acting insulin analogs are preferred over insulin NPH due to decreased risk of hypoglycemia (AACE [Blonde 2022]; ADA 2023; ADA [Chiang 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>General insulin dosing: </b></i>Insulin NPH is usually used in combination with a rapid or short-acting insulin. The daily doses presented are expressed as the<b> total units/kg/day of all insulin formulations combined</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial total daily insulin</i>: SUBQ: Initial: 0.4 to 0.5 units/kg/day in divided doses (AACE [Blonde 2022]; ADA 2023); usual range: 0.4 to 1 units/kg/day in divided doses (ADA 2023; Peters 2013; Silverstein 2005); lower doses (0.25 units/kg/day) may be used especially in young children to avoid potential hypoglycemia (Beck 2015); higher doses may be necessary for some patients (eg, concomitant steroids, puberty, sedentary lifestyle, obesity, following diabetic ketoacidosis presentation) (AACE [Blonde 2022]; Beck 2015; Peters 2013).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Usual total daily maintenance range:</i> SUBQ: Doses must be individualized; however, an estimate can be determined based on phase of diabetes and level of maturity (ISPAD [Cengiz 2022]; ISPAD [Sundberg 2022]):</p>
<p style="text-indent:-2em;margin-left:10em;">Partial remission phase ("Honeymoon phase"): &lt;0.5 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">Prepubertal children (not in partial remission):</p>
<p style="text-indent:-2em;margin-left:12em;">Infants ≥6 months and Children ≤6 years: 0.4 to 0.8 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:12em;">Children ≥7 years: 0.7 to 1 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">Pubescent Children and Adolescents: During puberty, requirements may substantially increase to &gt;1 unit/kg/day and in some cases up to 2 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Division of daily insulin requirement (multiple daily injections): </i></p>
<p style="text-indent:-2em;margin-left:10em;">Basal insulin: Generally, ~30% to 50% of the total daily insulin is given as basal insulin (intermediate- or long-acting) (AACE [Blonde 2022]; ADA 2023; ISPAD [Cengiz 2022]; Peters 2013). Insulin NPH may be administered in 2 divided doses; alternatively, dividing the total daily dose of insulin NPH into 3 or 4 doses per day may reduce hypoglycemic risk and establish a more consistent basal insulin profile (Peters 2013).</p>
<p style="text-indent:-2em;margin-left:10em;">Prandial insulin: The remaining portion of the total daily dose is then divided and administered before or at mealtimes (depending on the formulation) as rapid-acting (eg, aspart, glulisine, lispro) or short-acting (regular). In most type 1 patients, the use of a rapid-acting insulin analog is preferred over regular insulin to reduce hypoglycemia risk (AACE [Blonde 2022]; ADA 2023; ADA [Chiang 2014]; ISPAD [Cengiz 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage adjustment:</b> Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Treatment and monitoring regimens must be individualized to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Surgical patients</i>: <b>Note:</b> Patients with diabetes should be scheduled as the first case of the day (ISPAD [Kapellen 2022]).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Minor surgeries (surgery lasting &lt;2 hours, with or without sedation or anesthesia, where rapid recovery is anticipated and patient is expected to be able to eat within 2 to 4 hours):</i></p>
<p style="text-indent:-2em;margin-left:10em;">Morning or afternoon procedure: Administer 50% to 70% of the usual morning dose of insulin NPH; consider beginning IV fluids containing dextrose to decrease the risk of hypoglycemia. Alternatively, may administer IV insulin (regular) infusion; begin IV fluids containing dextrose. In general, rapid-acting insulin should be omitted until after surgery and patient is able to eat unless it is needed to correct significant hyperglycemia and/or significant ketone (&gt;0.6 mmol/L) production is present (ADA 2023; ISPAD [Kapellen 2022]; Peters 2013).</p>
<p style="text-indent:-2em;margin-left:10em;">Postprocedure: Once normal oral intake is achieved, resume usual insulin regimen; monitor closely due to changes related to surgery (ie, oral intake, nausea, postoperative stress, pain, inactivity).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Major surgeries (any surgery under anesthesia that is more than minor, typically lasting &gt;2 hours with a high likelihood of postoperative nausea, vomiting, and/or inability to adequately feed after procedure):</i></p>
<p style="text-indent:-2em;margin-left:10em;">Evening prior to surgery: If patient normally receives evening insulin, administer 50% to 70% of the usual evening insulin NPH dose (ISPAD [Kapellen 2022]; Peters 2013).</p>
<p style="text-indent:-2em;margin-left:10em;">Morning of surgery: Omit morning insulin (short and long acting) and start IV insulin (regular) infusion and IV fluids containing dextrose.</p>
<p style="text-indent:-2em;margin-left:10em;">Postprocedure: Once normal oral intake is achieved, resume usual insulin regimen; monitor closely; insulin requirements may vary due to changes related to surgery (ie, postoperative stress, medication changes, inactivity).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="570f091a-c1c1-46a6-9d95-172eadddf365">Diabetes mellitus, type 2</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Newly diagnosed patients:</i>
<b> Note: </b>Recommended for use in metabolically unstable patients (eg, plasma glucose ≥250 mg/dL, HbA<sub>1c</sub> &gt;8.5%, and symptoms excluding acidosis) while metformin is initiated and titrated; may also be used for patients with ketosis to correct the hyperglycemia and the metabolic derangement (ADA 2023; ADA [Arslanian 2018]; ISPAD [Shah 2022].</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥10 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial therapy: SUBQ: Initial: 0.25 to 0.5 units/kg/dose once daily; titrate every 2 to 3 days as needed based on plasma glucose; use in combination with lifestyle changes and metformin to achieve goals (ADA 2023; ADA [Arslanian 2018]; ISPAD [Shah 2022]).</p>
<p style="text-indent:-2em;margin-left:8em;">Subsequent therapy:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Glycemic goal achieved:</i> SUBQ: Once initial goal reached, insulin should be slowly tapered over 2 to 6 weeks by decreasing the insulin dose by 30% to 50% each time the metformin dose is increased and the patient transitioned to metformin monotherapy if able (ISPAD [Shah 2022]).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Glycemic goal NOT achieved:</i> In patients in whom glycemic goals are not achieved with insulin NPH (up to 1.5 units/kg/day) and maximum metformin dose, consider initiating prandial insulin (regular insulin or rapid-acting insulin) (ADA 2023; ISPAD [Shah 2022]). <b>Note: </b>Insulin resistance is common with type 2 diabetes and doses &gt;1.5 units/kg/day may be necessary to achieve glycemic control, especially in patients with high A<sub>1c</sub> and patients in mid to late puberty (ADA [Arslanian 2018]).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51114027"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>
<div class="block dohp drugH1Div" id="F51114028"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>
<div class="block adr drugH1Div" id="F2135510"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Injection site pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amyloidosis (cutaneous at injection site), hypoglycemia, hypokalemia, lipodystrophy, lipohypertrophy, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Immunogenicity</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Atrophy at injection site, erythema at injection site, hypertrophy at injection site, injection site reaction, swelling at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Swelling of extremities</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance</p></div>
<div class="block coi drugH1Div" id="F2136091"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to insulin NPH or any component of the formulation; during periods of hypoglycemia</p></div>
<div class="block war drugH1Div" id="F2135506"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Glycemic control: Hyper- or hypoglycemia may result from changes in insulin strength, manufacturer, type, and/or administration method. The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from changes in meal pattern (eg, macronutrient content, timing of meals), changes in the level of physical activity, increased work or exercise without eating, or changes to coadministered medications. Use of long-acting insulin preparations (eg, insulin degludec, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Patients with renal or hepatic impairment may be at a higher risk. Symptoms differ in patients and may change over time in the same patient; awareness may be less pronounced in those with long-standing diabetes, diabetic nerve disease, patients taking beta-blockers, or in those who experience recurrent hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage, or even death. Insulin requirements may be altered during illness, emotional disturbances, or other stressors. Instruct patients to use caution with ethanol; may increase risk of hypoglycemia. In clinical trials insulin NPH has been associated with a modestly increased risk of hypoglycemia (including nocturnal hypoglycemia) compared with long-acting analogs (Lipska 2017; Rosenstock 2005; Rys 2015; Singh 2009). However, an observational study in patients with type 2 diabetes from a large health care delivery system found no difference in the incidence of ER visits or hospitalization for hypoglycemia with NPH compared with glargine/detemir when treating to conventional targets in a real world setting (Lipska 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (serious, life-threatening and anaphylaxis) have occurred. If hypersensitivity reactions occur, discontinue administration and initiate supportive care measures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: Insulin (especially IV insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium and supplement potassium when necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">– Type 2 diabetes, hypoglycemia: Closely monitor insulin dose requirement throughout active weight loss with a goal of eliminating antidiabetic therapy or transitioning to agents without hypoglycemic potential; hypoglycemia after gastric bypass, sleeve gastrectomy, and gastric band may occur (Mechanick 2020). Insulin secretion and sensitivity may be partially or completely restored after these procedures (Korner 2009; Peterli 2012). Rates and timing of type 2 diabetes improvement and resolution vary widely by patient. Insulin dose reduction of ≥75% has been suggested after gastric bypass for patients without severe β-cell failure (fasting c-peptide &lt;0.3 nmol/L) (Cruijsen 2014). Avoid the use of bolus insulin injections or dose conservatively with close clinical monitoring in the early phases after surgery.</p>
<p style="text-indent:-2em;margin-left:6em;">– Weight gain: Insulin therapy is preferred if antidiabetic therapy is required during the perioperative period (Mechanick 2019). Evaluate risk versus benefit of long-term postoperative use and consider alternative therapy due to potential for insulin-induced weight gain (Apovian 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac disease: Concurrent use with peroxisome proliferator-activated receptor (PPAR)-gamma agonists, including thiazolidinediones (TZDs) may cause dose-related fluid retention and lead to or exacerbate heart failure, particularly when used in combination with insulin. If PPAR-gamma agonists are prescribed, monitor for signs and symptoms of heart failure. If heart failure develops, consider PPAR-gamma agonist dosage reduction or therapy discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage requirements may be reduced.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment. Dosage requirements may be reduced.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hospitalized patients with diabetes: Exclusive use of a sliding scale insulin regimen (insulin regular) in the inpatient hospital setting is strongly discouraged. In the critical care setting, continuous IV insulin infusion (insulin regular) has been shown to best achieve glycemic targets. In noncritically ill patients with either poor oral intake or taking nothing by mouth, <b>basal </b>insulin or <b>basal</b> plus bolus is preferred. In noncritically ill patients with adequate nutritional intake, a combination of <b>basal </b>insulin, nutritional, and correction components is preferred. An effective insulin regimen will achieve the goal glucose range without the risk of severe hypoglycemia). A blood glucose value &lt;70 mg/dL should prompt a treatment regimen review and change, if necessary, to prevent further hypoglycemia (ADA 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC, 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Insulin NPH is <b>NOT</b> intended for IV or IM administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.</p></div>
<div class="block foc drugH1Div" id="F2104236"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HumuLIN N: 100 units/mL (3 mL [DSC], 10 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovoLIN N: 100 units/mL (10 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovoLIN N ReliOn: 100 units/mL (10 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HumuLIN N KwikPen: 100 units/mL (3 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovoLIN N FlexPen: 100 units/mL (3 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovoLIN N FlexPen ReliOn: 100 units/mL (3 mL) [contains metacresol, phenol]</p></div>
<div class="block geq drugH1Div" id="F2135496"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F3422166"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (HumuLIN N Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $5.35</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (NovoLIN N ReliOn Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $5.78</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (NovoLIN N Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $5.78</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Pen-injector</b> (HumuLIN N KwikPen Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $11.31</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Pen-injector</b> (NovoLIN N FlexPen ReliOn Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $7.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Pen-injector</b> (NovoLIN N FlexPen Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $7.29</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F2136098"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> For subcutaneous administration into the thigh, upper arm, buttocks, or abdomen; do <b>not</b> administer IM or IV, or in an insulin pump. Absorption rates vary amongst injection sites; be consistent with area used while rotating injection sites within the same region to reduce the risk of lipodystrophy or localized cutaneous amyloidosis. Rotating from an injection site where lipodystrophy/cutaneous amyloidosis is present to an unaffected site may increase risk of hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:2em;">In order to properly resuspend the insulin, vials should be carefully inverted or rolled at least 10 times, Humulin N KwikPen should be rolled between the palms ten times and inverted 180° ten times, and Novolin N FlexPen should be inverted 180° twenty times prior to the first injection and ten times thereafter. Cartridges [Canadian product] should be inverted 180° at least ten times. Properly resuspended insulin NPH should look uniformly cloudy or milky; do not use if any white insulin substance remains at the bottom of the container, if any clumps are present, or if white particles are stuck to the bottom or wall of the container. Cold injections should be avoided.</p>
<p style="text-indent:-2em;margin-left:2em;">Per the manufacturer labeling, Humulin N from a vial may be mixed with insulin lispro or insulin regular and Novolin N from a vial may be mixed only with insulin regular. When mixing insulin NPH with other insulins in a syringe, insulin NPH should be drawn into the syringe <b>after</b> the other insulin preparations. Do not dilute or mix other insulin formulations with insulin NPH contained in a cartridge [Canadian product] or prefilled pen. When there are less than 12 units remaining in Novolin N FlexPen, replace it with a new one to ensure even mixing.</p>
<p style="text-indent:-2em;margin-left:2em;">For prefilled pens, prime the needle before each injection with 2 units of insulin. Once injected, hold the needle in the skin for at least 5 seconds (Humulin N KwikPen) or at least 6 seconds (Novolin N FlexPen) after the dose dial has returned to 0 units before removing the needle to ensure the full dose has been administered.</p></div>
<div class="block admp drugH1Div" id="F52614183"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">SUBQ: Administer subcutaneously into the thigh, upper arm, buttocks, or abdomen; do not administer IM, IV, or in an insulin pump. Rotate injection sites within the same region to reduce the risk of lipodystrophy or localized cutaneous amyloidosis; rotating from an injection site where lipodystrophy/cutaneous amyloidosis is present to an unaffected site may increase risk of hypoglycemia. Properly resuspended insulin NPH should look uniformly white; resuspension is easier when the insulin is at room temperature. Do not use if any white insulin substance remains at the bottom of the container, if any clumps are present, or if white particles are stuck to the bottom or wall of the container. Cold injections should be avoided.</p>
<p style="text-indent:-2em;margin-left:2em;">Vials: In order to properly resuspend the insulin, gently roll the vial horizontally between the palms 10 times. Per the manufacturer's labeling, Humulin N from a vial may be mixed with insulin lispro or insulin regular and Novolin N from a vial may be mixed only with insulin regular. When mixing insulin NPH with other insulins in a syringe, insulin NPH should be drawn into the syringe <b>after</b> the other insulin preparations.</p>
<p style="text-indent:-2em;margin-left:2em;">Prefilled pens: Do not dilute or mix other insulin formulations with insulin NPH contained in a cartridge or prefilled pen.</p>
<p style="text-indent:-2em;margin-left:4em;">Humulin N KwikPen: In order to properly resuspend the insulin, the pen should be rolled between the palms 10 times and inverted 180° 10 times. Prime the needle before each injection with 2 units of insulin; see manufacturer's labeling for specific procedure. Humulin N KwikPen is designed to administer doses in 1-unit increments and can deliver up to 60 units as a single injection. Once primed, set dial to the appropriate dose, insert needle into clean skin, and activate device; once insulin is injected, hold the needle in the skin for at least 5 seconds, keeping the button pressed the entire time, and then remove the needle. Check to see if there is a "0" in the dose window, which indicates that the full dose has been administered. If there is no "0" in the dose window, insert needle into the skin and finish injection. Do not redial. If dose is &gt;60 units, more than 1 injection will be required; split dose and administer in multiple injections. Do not rub the injection area. If the dose required is larger than the units left on the pen, either administer amount left in pen and give second injection from a new pen to complete the dose or discard pen and use a new pen to complete whole dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Novolin N FlexPen: In order to properly resuspend the insulin, the pen should be inverted 180° 20 times prior to the first injection and 10 times thereafter. Novolin N FlexPen is designed to administer doses in 1-unit increments and can deliver up to 60 units as a single injection. Once primed, set dial to the appropriate dose, insert needle into clean skin, and activate device. Once insulin is injected, hold the needle in the skin for at least 6 seconds, keeping the button pressed the entire time, and then remove the needle. Do not rub the area. When there are &lt;12 units remaining in Novolin N FlexPen, replace it with a new one to ensure even mixing.</p></div>
<div class="block use drugH1Div" id="F2135501"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diabetes mellitus, types 1 and 2, treatment: </b>Treatment of types 1 and 2 diabetes mellitus to improve glycemic control in adults and pediatric patients.</p></div>
<div class="block off-label drugH1Div" id="F25726565"><span class="drugH1">Use: Off-Label: Adult</span><p>Gestational diabetes mellitus</p></div>
<div class="block mst drugH1Div" id="F2136087"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HumuLIN N may be confused with HumuLIN R, HumaLOG, Humira</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovoLIN N may be confused with NovoLIN R, NovoLOG </p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. <b>
<i>Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.</i></b></p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F2135518"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F2135517"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Glucosidase Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with an alpha-glucosidase inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Insulins. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Insulins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Insulins. Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Glucose Lowering Effects: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Liraglutide: May enhance the hypoglycemic effect of Insulins. Management: Consider reducing the liraglutide dose if coadministered with insulin. Prescribing information for the Saxenda brand of liraglutide recommends a dose decrease of 50%. Monitor blood glucose for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Insulins may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metreleptin: May enhance the hypoglycemic effect of Insulins. Management: Insulin dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely for signs and symptoms of hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pioglitazone: May enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination. Management: If insulin is combined with pioglitazone, consider insulin dose reductions to avoid hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure, and consider pioglitazone dose reduction or discontinuation if heart failure occurs<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the hypoglycemic effect of Insulins. Management: Upon initiation of pramlintide, decrease mealtime insulin dose by 50% to reduce the risk of hypoglycemia. Monitor blood glucose frequently and individualize further insulin dose adjustments based on glycemic control.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosiglitazone: Insulins may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F2135504"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia (ACOG 201 2018). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2022; Blumer 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, insulin requirements tend to increase as pregnancy progresses, requiring frequent monitoring and dosage adjustments. Following delivery, insulin requirements decrease rapidly (ACOG 201 2018; ADA 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Insulin is the preferred treatment of type 1 and type 2 diabetes mellitus in pregnancy, as well as gestational diabetes mellitus, when pharmacologic therapy is needed (ACOG 190 2018; ACOG 201 2018; ADA 2022). NPH insulin may be used to treat diabetes mellitus in pregnancy (ACOG 190 2018; ACOG 201 2018; Blumer 2013)</p></div>
<div class="block brc drugH1Div" id="F2136090"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Both exogenous and endogenous insulin are present in breast milk (study not conducted with this preparation) (Whitmore 2012). Insulin is not systemically absorbed via breast milk but may provide local benefits to the infant GI tract (Anderson 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Appropriate glycemic control is required for the establishment of lactation in patients with diabetes mellitus (Anderson 2018). Breastfeeding provides metabolic benefits to mothers with type 1, type 2, and gestational diabetes mellitus as well as their infants; therefore, breastfeeding is encouraged (ACOG 201 2018; ADA 2022; Blumer 2013). Breastfeeding also influences maternal glucose tolerance; close monitoring of patients treated with insulin is recommended as dose adjustments may be required (ADA 2022; Anderson 2018). A small snack before breastfeeding may help decrease the risk of hypoglycemia in patients with pregestational diabetes (ACOG 201 2018; Reader 2004). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F2136097"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.</p></div>
<div class="block mop drugH1Div" id="F2136100"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Diabetes mellitus: Blood glucose (individualize frequency based on treatment regimen, hypoglycemia risk, and other patient-specific factors) (ADA 2022); electrolytes; renal function; hepatic function; weight.</p>
<p style="text-indent:-2em;margin-left:2em;">Gestational diabetes mellitus: Blood glucose 4 times daily (1 fasting and 3 postprandial) until well controlled, then as appropriate (ACOG 190 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Hospitalized patients: In patients who are eating, monitor blood glucose before meals and at bedtime; in patients who are not eating or are receiving continuous enteral feeds, monitor blood glucose every 4 to 6 hours (ADA 2022; ES [Umpierrez 2012]). More frequent monitoring may be required in some cases (eg, recurrent hypoglycemia, changes in nutrition, medication changes affecting glycemic control) (ES [Umpierrez 2012]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>HbA<sub>1c</sub></i>: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. <b>Note: </b>In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA<sub>1c</sub> is discordant with serum glucose levels or symptoms, consider evaluating HbA<sub>1c</sub> in combination with blood glucose levels and/or a glucose management indicator (ADA 2022; KDIGO 2020).</p></div>
<div class="block rer drugH1Div" id="F2135525"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommendations for glycemic control in patients with diabetes:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonpregnant adults (AACE [Samson 2023]; ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics). <b>Note</b>
<b>: </b>In patients using a continuous glucose monitoring system, a goal of time in range &gt;70% with time below range &lt;4% is recommended and is similar to a goal HbA<sub>1c</sub> &lt;7%.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:6em;">Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): &lt;180 mg/dL (SI: &lt;10 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Older adults (≥65 years of age) (ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% to 7.5% (healthy); &lt;8% (complex/intermediate health). <b>Note: </b>Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA<sub>1c</sub> level.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (healthy); 90 to 150 mg/dL (SI: 5 to 8.3 mmol/L) (complex/intermediate health); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:6em;">Bedtime capillary blood glucose: 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L) (healthy); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (complex/intermediate health); 110 to 200 mg/dL (SI: 6.1 to 11.1 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pregnant patients:</i></p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: Pregestational diabetes (type 1 or type 2) (ADA 2023):</p>
<p style="text-indent:-2em;margin-left:8em;">Preconception (patients planning for pregnancy): &lt;6.5%.</p>
<p style="text-indent:-2em;margin-left:8em;">During pregnancy &lt;6% (if can be achieved without significant hypoglycemia) or &lt;7% if needed to prevent hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:6em;">Capillary blood glucose: <b>Note: </b>Less stringent targets may be appropriate if goals cannot be achieved without causing significant hypoglycemia (ADA 2023).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Gestational diabetes mellitus (ACOG 190 2018; ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:10em;">Fasting: &lt;95 mg/dL (SI: &lt;5.3 mmol/L).</p>
<p style="text-indent:-2em;margin-left:10em;">Postprandial: &lt;140 mg/dL (SI: &lt;7.8 mmol/L) (at 1 hour) or &lt;120 mg/dL (SI: &lt;6.7 mmol/L) (at 2 hours).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Pregestational diabetes mellitus (type 1 or type 2) (ADA 2023</i>
<i>):</i></p>
<p style="text-indent:-2em;margin-left:10em;">Fasting: 70 to 95 mg/dL (SI: 3.9 to 5.3 mmol/L).</p>
<p style="text-indent:-2em;margin-left:10em;">Postprandial: 110 to 140 mg/dL (SI: 6.1 to 7.8 mmol/L) (at 1 hour) <b>or</b> 100 to 120 mg/dL (SI: 5.6 to 6.7 mmol/L) (at 2 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hospitalized adult patients (ADA 2023):</i> Target glucose range: 140 to 180 mg/dL (SI: 7.8 to 10 mmol/L) (majority of critically ill and noncritically ill patients; &lt;140 mg/dL (SI: &lt;7.8 mmol/L) may be appropriate for selected patients, if it can be achieved without excessive hypoglycemia). Initiate insulin therapy for persistent hyperglycemia at ≥180 mg/dL (SI: ≥10 mmol/L).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Perioperative care in adult patients (ADA 2023):</i> Target glucose range during perioperative period: Consider targeting 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Children and adolescents:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial glucose: 70 to 130 mg/dL (SI: 3.9 to 7.2 mmol/L) (ISPAD [Dimeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:6em;">Postprandial glucose: 90 to 180 mg/dL (SI: 5 to 10 mmol/L) (ISPAD [Dimeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:6em;">Bedtime/overnight glucose: 80 to 140 mg/dL (SI: 4.4 to 7.8 mmol/L) (ISPAD [Dimeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7%; target should be individualized; a more stringent goal (&lt;6.5%) may be reasonable if it can be achieved without significant hypoglycemia; less aggressive goals (&lt;7.5% or &lt;8%) may be appropriate in patients who cannot articulate symptoms of hypoglycemia, cannot check glucose frequently, have a history of severe hypoglycemia, or have extensive comorbid conditions (ADA 2023; ISPAD [Dimeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:6em;">Surgical patients (ISPAD [Jefferies 2018]):</p>
<p style="text-indent:-2em;margin-left:8em;">Intraoperative: 90 to 180 mg/dL (SI: 5 to 10 mmol/L).</p>
<p style="text-indent:-2em;margin-left:8em;">ICU, postsurgery: 140 to 180 mg/dL (SI: 7.8 to 10 mmol/L).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Classification of hypoglycemia (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Level 1: 54 to 70 mg/dL (SI: 3 to 3.9 mmol/L); hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 2: &lt;54 mg/dL (SI: &lt;3 mmol/L); threshold for neuroglycopenic symptoms; requires immediate action.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.</p></div>
<div class="block pha drugH1Div" id="F2135523"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.</p>
<p style="text-indent:0em;margin-top:2em;">Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Insulin stimulates lipoprotein lipase synthesis and activity; this results in hydrolysis of triglycerides into free fatty acids and storage of free fatty acids in adipocytes, thereby reducing circulating triglyceride levels (Rawla 2018; Sadur 1982; Song 2019). In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.</p>
<p style="text-indent:0em;margin-top:2em;">Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either <i>E. coli</i> or <i>Saccharomyces cerevisiae</i>. Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin NPH, an isophane suspension of human insulin, is an intermediate-acting insulin.</p></div>
<div class="block phk drugH1Div" id="F2136093"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Onset and duration of hypoglycemic effects depend upon the route of administration (absorption and onset of action are more rapid after deeper IM injections than after SUBQ), site of injection (onset and duration are progressively slower with SUBQ injection into the abdomen, arm, buttock, or thigh respectively), volume and concentration of injection, and the preparation administered. Rate of absorption, onset, and duration of activity may be affected by exercise, presence of lipodystrophy, local blood supply, and/or temperature.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Onset of action: 1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: 4 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 14 to 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 6 to 10 hours.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869460"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Humulin nph | Insulin Insulatard HM | Jusline n</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Betalin nph | Biohulin nph | Densulin n | Humulin n | Insulatard hm | Insulina humulin n | Insulina insulatard hm | Insuman n | Novolin n</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Huminsulin basal | Insulatard | Insulin Insulatard HM | Insuman basal</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Humulin nph | Protaphane</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Ansulin N | Humulin n | Insulatard | Insulatard hm | Insuman basal</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Humuline nph | Insulatard | Insuman basal | Protaphane hm</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Insulatard | Insulet nph</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Humaject nph | Humulin n | Humulin nph | Insulatard | Insulatard hm | Insuman basal | Protaphane hm</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bahiafarma insulina humana nph | Biohulin nph | Humulin n | Insulina humana recombinante nph | Insuman n | Novolin n | Visulin n | Wosulin n</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Huminsulin basal (nph) | Insulatard hm</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Insuman basal</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Insulatard hm</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Gan shu lin n | Humulin n | Humulin nph | Insulatard | Isophane protamine biosynthetic human Insulin | Novolin n | Protamine zinc recombinant human insulin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Gansulin n | Humulin n | Humulin nph | Insugen n | Insulex N | Insuman n | Wosulin n</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Insulatard | Insulatard hm | Insulin hm nph | Insuman basal | Protaphane</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Basal-h-insulin | Huma Ject Basal | Huminsulin basal | Insulatard | Insulin B. Braun Basal | Insulin B. Braun ratiopharm basal | Insuman basal | Protaphane</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Insulatard</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Humulin nph | Insulatard hm | Insuman n | Novolin n | Recomulin n</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Insulatard hm | Insulina Isofana Humana | Insuman n | Novolin n</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Humaject N | Humulin n | Insuman basal | Isuhuman basal | Protaphane hm</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Humulin nph | Insulatard | Insulin H NPH | Insulin N | Insulinagypt n | Insuman basal</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Humaplus nph | Humulina nph | Insulatard humana | Insulatard nph</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Humulin nph | Insuman basal | Protaphane</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Insulatard | Insuman basal | Lillypen nph | Umuline nph</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Humulin i | Insulatard | Insuman basal | Protaphane human</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Humaject nph | Humulin nph | Insulatard | Protaphane | Protaphane hm</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Protaphane hm</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Insulatard | Insuman basal</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Insulatard | Insulin insulatard hm(ge) | Insuman basal | Protaphane hm</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Insulatard | Insulatard hm | Insuman basal | Protaphane hm</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Humulin i | Insulatard</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Humulin nph | Insulatard hm</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Human insulatard | Humanext N | Huminsulin-n | Insucare N | Insugen n | Insulatard | Insuman basal | Recosulin-n | Univia n | Wosulin n</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bio insulin i | Humulin i | Protaphane</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Gensulin n | Humulin nph | Insulatard hm</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Humacart n | Humulin n | Innolet n | Novolin n</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Humodar b | Humulin n | Insulatard | Jusline n</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Biohulin nph | Humaject N | Humulin n | Insulatard | Insulatard Human | Novolet N | Novolin n | Protaphane hm</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Humulin nph | Insulatard hm | Insulin insulatard</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Humulin nph | Insulin Insulatard HM | Insuman basal</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Humulin nph | Insulatard hm | Protaphane | Protaphane hm</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Humaject nph | Humuline nph | Insulatard</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Humulin i | Humulin n | Insulatard hm | Insuman basal | Protaphane | Protaphane hm</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Insulatard hm | Insulet nph | Lillypen nph | Umuline nph | Umuline protamine isophane (nph)</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Insulex N | Insulina Nph | Insuman n | Novolin n</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Insulatard | Insulatard hm | Protaphane hm</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Humuline nph | Insulatard | Insuman basal</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Humulin nph | Insulatard | Insuman basal</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Humulin nph | Protaphane</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Humulin nph | Insulatard hm | Insulina Isofana Humana | Insuman n | Wosulin n</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Glysolin n | Humulin n | Insuget N | Insulatard | Insulatard hm | Insulyf n | Jusline n | Scilin n</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Dongsulin N | Humulin nph | Innogen N | Insuget N | Insulatard | Insulatard hm | Insuman basal | Protaphane hm | Zansulin n.p.h</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Gensulin n | Humaject N | Humulin n | Insulatard | Insulatard hm | Insulatard nph | Insuman basal</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Insulatard nph human | Novolin n | Relion/Novolin N</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Humulin nph | Insulatard</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Biohulin n | Biohulin n humana | Humulin n | Insulatard humana | Insulina nph humana | Insuman n | Sulina n</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Humulin N | Insulatard | Insulatard Penfill | Insuman Basal</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Insulatard | Insuman basal</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Biosulin n | Diaphan hsp | Gansulin n | Humodar b | Humodar b rec | Humulin n | Humulin nph | Insuman basal | Insuman Basal Gt | Insuran nph | Protamin Insulin HS | Protaphane hm | Rinsulin nph | Rosinsulin s | Wozulim n</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Humulin nph | Insulatard hm</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Humulin nph | Insulatard | Insuman basal | Protaphane</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Insulatard</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Humulin nph | Insulin Insulatard HM | Insuman basal</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Insulatard hm | Insulin hm nph | Insuman basal</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Biosulin n | Humulin n | Insulatard hm | Insulatard hm novo | Protaphane hm | Winsulin n</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Insulatard hm | Insuman basal | Jusline n</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Humulin nph | Insulatard | Insulin Insulatard HM</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Insulatard | Insulatard hm | Protaphane | Protaphane hm</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Humodar b | Humulin nph | Insugen n | Protaphane | Protaphane hm</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Biosulin n | Gensulin n | Humulin n | Insugen n | Insulatard hm | Wosulin n</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Insulatard</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Humulin n | Humulin nph | Insuman nph | Novolin n</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Biosulin n | Humaject N | Humulin n | Insuman basal | Protaphane</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30461693">
<a name="30461693"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 201: Pregestational diabetes mellitus. <i>Obstet Gynecol.</i> 2018;132(6):e228-e248. doi: 10.1097/AOG.0000000000002960.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/30461693/pubmed" id="30461693" target="_blank">30461693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29370047">
<a name="29370047"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. <i>Obstet Gynecol</i>. 2018;131(2):e49-e64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/29370047/pubmed" id="29370047" target="_blank">29370047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2023">
<a name="ADA.2023"></a>American Diabetes Association (ADA). Standards of care in diabetes – 2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29608329">
<a name="29608329"></a>Anderson PO. Treating diabetes during breastfeeding. <i>Breastfeed Med</i>. 2018;13(4):237-239. doi:10.1089/bfm.2018.0036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/29608329/pubmed" id="29608329" target="_blank">29608329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25590212">
<a name="25590212"></a>Apovian CM, Aronne LJ, Bessesen DH, et al; Endocrine Society. Pharmacological management of obesity: an Endocrine Society clinical practice guideline [published correction appears in <i>J Clin Endocrinol Metab</i>. 2015;100(5):2135-2136]. <i>J Clin Endocrinol Metab</i>. 2015;100(2):342-362. doi: 10.1210/jc.2014-3415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/25590212/pubmed" id="25590212" target="_blank">25590212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30425094">
<a name="30425094"></a>Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American Diabetes Association. <i>Diabetes Care</i>. 2018;41(12):2648-2668.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/30425094/pubmed" id="30425094" target="_blank">30425094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472948">
<a name="26472948"></a>Beck JK, Cogen FR. Outpatient management of pediatric type 1 diabetes. <i>J Pediatr Pharmacol Ther</i>. 2015;20(5):344-357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/26472948/pubmed" id="26472948" target="_blank">26472948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35963508">
<a name="35963508"></a>Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology (AACE) clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. <i>Endocr Pract</i>. 2022;28(10):923-1049. doi:10.1016/j.eprac.2022.08.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/35963508/pubmed" id="35963508" target="_blank">35963508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24194617">
<a name="24194617"></a>Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/24194617/pubmed" id="24194617" target="_blank">24194617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537533">
<a name="36537533"></a>Cengiz E, Danne T, Ahmad T, et al. ISPAD clinical practice consensus guidelines 2022: insulin treatment in children and adolescents with diabetes. <i>Pediatr Diabetes</i>. 2022;23(8):1277-1296. doi:10.1111/pedi.13442<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/36537533/pubmed" id="36537533" target="_blank">36537533</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. <a href="https://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html" target="_blank">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed January 9, 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935775">
<a name="24935775"></a>Chiang JL, Kirkman MS, Laffel LM, et al; Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. <i>Diabetes Care</i>. 2014;37(7):2034-2054. doi: 10.2337/dc14-1140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/24935775/pubmed" id="24935775" target="_blank">24935775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24829176">
<a name="24829176"></a>Cruijsen M, Koehestani P, Huttjes S, Leenders K, Janssen I, de Boer H. Perioperative glycaemic control in insulin-treated type 2 diabetes patients undergoing gastric bypass surgery. <i>Neth J Med</i>. 2014;72(4):202-209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/24829176/pubmed" id="24829176" target="_blank">24829176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25182312">
<a name="25182312"></a>Danne T, Bangstad HJ, Deeb L, Jarosz-Chobot P, Mungaie L, et al; International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Insulin treatment in children and adolescents with diabetes. <i>Pediatr Diabetes</i>. 2014;15 (suppl 20):115-134. doi:10.1111/pedi.12184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/25182312/pubmed" id="25182312" target="_blank">25182312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30288571">
<a name="30288571"></a>Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i>. 2018;61(12):2461-2498. doi:10.1007/s00125-018-4729-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/30288571/pubmed" id="30288571" target="_blank">30288571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537523">
<a name="36537523"></a>de Bock M, Codner E, Craig ME, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. <i>Pediatr Diabetes</i>. 2022;23(8):1270-1276. doi:10.1111/pedi.13455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/36537523/pubmed" id="36537523" target="_blank">36537523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30058221">
<a name="30058221"></a>DiMeglio LA, Acerini CL, Codner E, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. <i>Pediatr Diabetes</i>. 2018;19(Suppl 27):105-114. doi:10.1111/pedi.12737<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/30058221/pubmed" id="30058221" target="_blank">30058221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. <i>Endocr Pract.</i> 2020;26(1):107-139. doi:10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25869408">
<a name="25869408"></a>Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. <i>Endocr Pract</i>. 2015;21(suppl 1):S1-S87. https://journals.aace.com/doi/pdf/10.4158/EP15672.GLSUPPL. Accessed April 22, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/25869408/pubmed" id="25869408" target="_blank">25869408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HumulinN.1">
<a name="HumulinN.1"></a>Humulin N (human insulin isophane [rDNA origin]) suspension injection [prescribing information]. Indianapolis, IN: Eli Lilly and Company; March 2023.</div>
</li>
<li>
<div class="reference">
                  Humulin N KwikPen (human insulin [rDNA origin] isophane suspension) [prescribing information]. Indianapolis, IN: Eli Lilly; January 2017.</div>
</li>
<li>
<div class="reference">
                  Humulin R, Humulin N, and Humulin 30/70 (insulin isophane, human biosynthetic [rDNA origin]) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30039617">
<a name="30039617"></a>Jefferies C, Rhodes E, Rachmiel M, et al. ISPAD clinical practice consensus guidelines 2018: Management of children and adolescents with diabetes requiring surgery. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):227-236. doi:10.1111/pedi.12733<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/30039617/pubmed" id="30039617" target="_blank">30039617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537521">
<a name="36537521"></a>Kapellen T, Agwu JC, Martin L, et al. ISPAD clinical practice consensus guidelines 2022: management of children and adolescents with diabetes requiring surgery. <i>Pediatr Diabetes</i>. 2022;23(8):1468-1477. doi:10.1111/pedi.13446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/36537521/pubmed" id="36537521" target="_blank">36537521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khan.1">
<a name="Khan.1"></a>Khan NA, Ghali WA, Cagliero E. Perioperative management of blood glucose in adults with diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) diabetes work group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23106132">
<a name="23106132"></a>Kirkman M, Briscoe VJ, Clark N, et al, "Diabetes in Older Adults: A Consensus Report," <i>J Am Geriatr Soc</i>, 2012; doi: 10.1111/jgs.12035.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/23106132/pubmed" id="23106132" target="_blank">23106132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19417773">
<a name="19417773"></a>Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. <i>Int J Obes (Lond).</i> 2009;33(7):786-795. doi: 10.1038/ijo.2009.79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/19417773/pubmed" id="19417773" target="_blank">19417773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society* clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28604935">
<a name="28604935"></a>Lipska KJ, Hirsch IB, Riddle MC. Human insulin for type 2 diabetes: an effective, less-expensive option. <i>JAMA</i>. 2017;318(1):23-24. doi: 10.1001/jama.2017.6939.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/28604935/pubmed" id="28604935" target="_blank">28604935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29936529">
<a name="29936529"></a>Lipska KJ, Parker MM, Moffet HH, et al. Association of initiation of basal insulin analogs vs neutral protamine hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes. <i>JAMA</i>. 2018;320(1):53-62. doi: 10.1001/jama.2018.7993.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/29936529/pubmed" id="29936529" target="_blank">29936529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22575407">
<a name="22575407"></a>McCall AL. Insulin therapy and hypoglycemia. <i>Endocrinol Metab Clin North Am</i>. 2012;41(1):57-87. doi: 10.1016/j.ecl.2012.03.001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/22575407/pubmed" id="22575407" target="_blank">22575407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Novolin ge (human insulin biosynthetic) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada Inc; March 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novolin.2">
<a name="Novolin.2"></a>Novolin N (human insulin isophane suspension injection [rDNA origin]) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22354457">
<a name="22354457"></a>Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. <i>Obes Surg</i>. 2012;22(5):740-748. doi: 10.1007/s11695-012-0622-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/22354457/pubmed" id="22354457" target="_blank">22354457</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Peters AP, Laffel L, eds. <i>Type 1 Diabetes Sourcebook</i>. Alexandria, VA: American Diabetes Association; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22086363">
<a name="22086363"></a>Pichardo-Lowden A, Gabbay RA. Management of hyperglycemia during the perioperative period. <i>Curr Diab Rep</i>. 2012;12(1):108-118. doi:10.1007/s11892-011-0239-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/22086363/pubmed" id="22086363" target="_blank">22086363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29923163">
<a name="29923163"></a>Rawla P, Sunkara T, Thandra KC, Gaduputi V. Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies. <i>Clin J Gastroenterol</i>. 2018;11(6):441-448. doi:10.1007/s12328-018-0881-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/29923163/pubmed" id="29923163" target="_blank">29923163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15461903">
<a name="15461903"></a>Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. <i>Curr Diab Rep</i>. 2004;4(5):370-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/15461903/pubmed" id="15461903" target="_blank">15461903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15793205">
<a name="15793205"></a>Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. <i>Diabetes Care</i>. 2005;28(4):950-955.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/15793205/pubmed" id="15793205" target="_blank">15793205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25585592">
<a name="25585592"></a>Rys P, Wojciechowski P, Rogoz-Sitek A, et al. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. <i>Acta Diabetol</i>. 2015;52(4):649-662. doi: 10.1007/s00592-014-0698-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/25585592/pubmed" id="25585592" target="_blank">25585592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7040473">
<a name="7040473"></a>Sadur CN, Eckel RH. Insulin stimulation of adipose tissue lipoprotein lipase. Use of the euglycemic clamp technique. <i>J Clin Invest</i>. 1982;69(5):1119-1125. doi:10.1172/jci110547<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/7040473/pubmed" id="7040473" target="_blank">7040473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36161685">
<a name="36161685"></a>Shah AS, Zeitler PS, Wong J, et al. ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents. <i>Pediatr Diabetes</i>. 2022;23(7):872-902. doi:10.1111/pedi.13409<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/36161685/pubmed" id="36161685" target="_blank">36161685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15616254">
<a name="15616254"></a>Silverstein J, Klingensmith G, Copeland K, et al; American Diabetes Association. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. <i>Diabetes Care.</i> 2005;28(1):186-212. doi:10.2337/diacare.28.1.186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/15616254/pubmed" id="15616254" target="_blank">15616254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19221352">
<a name="19221352"></a>Singh SR, Ahmad F, Lal A, et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. <i>CMAJ</i>. 2009;180(4):385-397. doi: 10.1503/cmaj.081041.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/19221352/pubmed" id="19221352" target="_blank">19221352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31215460">
<a name="31215460"></a>Song X, Shi D, Cui Q, et al. Intensive insulin therapy versus plasmapheresis in the management of hypertriglyceridemia-induced acute pancreatitis (Bi-TPAI trial): study protocol for a randomized controlled trial. <i>Trials</i>. 2019;20(1):365. doi:10.1186/s13063-019-3498-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/31215460/pubmed" id="31215460" target="_blank">31215460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537520">
<a name="36537520"></a>Sundberg F, deBeaufort C, Krogvold L, et al. ISPAD clinical practice consensus guidelines 2022: managing diabetes in preschoolers. <i>Pediatr Diabetes</i>. 2022;23(8):1496-1511. doi:10.1111/pedi.13427<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/36537520/pubmed" id="36537520" target="_blank">36537520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22223765">
<a name="22223765"></a>Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2012;97(1):16-38. doi:10.1210/jc.2011-2098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/22223765/pubmed" id="22223765" target="_blank">22223765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.1">
<a name="Wexler.1"></a>Wexler DJ. Insulin therapy in type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed September 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22500167">
<a name="22500167"></a>Whitmore TJ, Trengove NJ, Graham DF, Hartmann PE. Analysis of insulin in human breast milk in mothers with type 1 and type 2 diabetes mellitus. <i>Int J Endocrinol</i>. 2012;2012:296368.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-nph-drug-information/abstract-text/22500167/pubmed" id="22500167" target="_blank">22500167</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9028 Version 276.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
